OVARIAN CANCER and US: single agent pegylated liposomal doxorubicin

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label single agent pegylated liposomal doxorubicin. Show all posts
Showing posts with label single agent pegylated liposomal doxorubicin. Show all posts

Monday, June 28, 2010

Reply to M. Markman -- Ferrandina 28 (19): e321 -- Journal of Clinical Oncology



Markman:  Serious Ethical Dilemma of Single-Agent Pegylated Liposomal Doxorubicin Employed As a Control Arm in Ovarian Cancer Chemotherapy Trials -- Markman JCO commentary

  Ferrandina Response to Markman:

http://jco.ascopubs.org/cgi/content/full/28/19/e321?cmpid=jco_etoc_1July2010
"...Overall, I think that there will be no need for institutional review boards of community-based centers or universities to take up a formal position in this context. Indeed, I think that the more and more diffuse use in the clinical practice of PLD 40 mg/m2 will be, in and by itself, stronger than any regulatory rules, and that the lower and safer PLD dose level will tacitly replace the US Food and Drug Administration–approved dosage in clinical trials.

Time has already come for this change: looking through the randomized clinical trials utilizing PLD as a control arm, we found that four (NCT00976911 [ClinicalTrials.gov] , NCT00913835 [ClinicalTrials.gov] , NCT00635193 [ClinicalTrials.gov] , NCT00657878 [ClinicalTrials.gov] ) of seven of the ongoing studies are already employing the PLD dosage of 40 mg/m2 instead of 50 mg/m2 (www.clinicaltrials.gov."